Acurx Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

NATURE OF OPERATIONS (Details)

NATURE OF OPERATIONS (Details) - USD ($)									1 Months Ended	3 Months Ended
NATURE OF OPERATIONS (Details) - USD ($)	Jun. 17, 2025	May 08, 2025	Mar. 06, 2025	Jan. 06, 2025	Nov. 15, 2023	May 18, 2023	Jul. 27, 2022	Jun. 29, 2021	Feb. 28, 2018	Mar. 31, 2026	Dec. 31, 2025	Jun. 23, 2021
Class of Stock [Line Items]
Share price (in dollars per share)								$ 120
Warrants issued (in shares)										0
Gross proceeds from stock issue						$ 4,000,000	$ 4,200,000	$ 17,300,000
Common stock, par value										$ 0.001	$ 0.001	$ 0.001
Cash										$ 9,254,813	$ 7,556,100
Series A warrants
Class of Stock [Line Items]
Warrants issued (in shares)							64,499
Series B warrants
Class of Stock [Line Items]
Warrants issued (in shares)							64,499
Series C warrants
Class of Stock [Line Items]
Warrants issued (in shares)						66,667
Series D warrants
Class of Stock [Line Items]
Warrants issued (in shares)						66,667
Pre-funded warrants
Class of Stock [Line Items]
Warrants issued (in shares)						36,574	6,538
Common Stock
Class of Stock [Line Items]
Shares issued (in shares)						30,093	57,961	143,750
At the Market Offering
Class of Stock [Line Items]
Shares issued to date (in shares)										141,516
Maximum value of offering					$ 17,000,000
Proceeds to date										$ 9,200,000
Equity Line of Credit Purchase Agreement
Class of Stock [Line Items]
Shares issued (in shares)		44,963								1,016,119
Share price (in dollars per share)		$ 3.09
Maximum value of offering		$ 12,000,000
Gross proceeds from stock issue										$ 3,134,998
Equity Line of Credit Purchase Agreement \| Common Stock
Class of Stock [Line Items]
Shares issued to date (in shares)		1,767,516
Maximum value of offering		$ 12,000,000
Proceeds to date		$ 7,100,000
Common stock, par value		$ 0.001
Warrant Inducement Agreement
Class of Stock [Line Items]
Warrant exercise price (in dollars per share)	$ 12
Warrants issued (in shares)	222,272
Gross proceeds from stock issue	$ 2,700,000
Proceeds from warrant exercise	$ 2,700,000
Warrant Inducement Agreement \| Series A warrants
Class of Stock [Line Items]
Warrant exercise price (in dollars per share)	$ 65
Warrants issued (in shares)	61,538
Warrant Inducement Agreement \| Series B warrants
Class of Stock [Line Items]
Warrant exercise price (in dollars per share)	$ 65
Warrants issued (in shares)	27,400
Warrant Inducement Agreement \| Series C warrants
Class of Stock [Line Items]
Warrant exercise price (in dollars per share)	$ 65.2
Warrants issued (in shares)	66,667
Warrant Inducement Agreement \| Series D warrants
Class of Stock [Line Items]
Warrant exercise price (in dollars per share)	$ 65.2
Warrants issued (in shares)	66,667
January 2025 Registered Direct Offering
Class of Stock [Line Items]
Share price (in dollars per share)				$ 20.3
Gross proceeds from stock issue				$ 2,500,000
January 2025 Registered Direct Offering \| Common Stock
Class of Stock [Line Items]
Shares issued (in shares)				123,153
March 2025 Registered Direct Offering
Class of Stock [Line Items]
Share price (in dollars per share)			$ 8
Gross proceeds from stock issue			$ 1,100,000
March 2025 Registered Direct Offering \| Pre-funded warrants
Class of Stock [Line Items]
Warrant exercise price (in dollars per share)			$ 7.998
Warrants issued (in shares)			29,750
March 2025 Registered Direct Offering \| Common Stock
Class of Stock [Line Items]
Shares issued (in shares)			107,500
ACX362E
Class of Stock [Line Items]
Cash paid									$ 110,174
Maximum milestone commitment									$ 700,000
Milestones paid to date										$ 200,000
Royalty payments on net sales (as a percent)									4.00%
ACX362E \| Members' Equity, Class B
Class of Stock [Line Items]
Interest granted in asset purchase (in shares)									100,000
Warrant exercise price (in dollars per share)									$ 0.1